Vertex,was ist da los???,kommen sie zurück ins PLUSSSSSSSSSS - 500 Beiträge pro Seite

[williaktie]

wer kann was über Vertex sagen, was ist los.??
ich dachte die geht ab ,nach oben wie schmidts Katze.
mfg

[strateger]

das dachte ich auch, schwach wegen schlechte meldung von imclone, agenix,etc....

[Nino_1128]

Hallo, Vertex wird bald abgehen wenn die Bios nachziehen. Potenzial nach unten begrenzt.
Dann noch die Meldung von Aurora von Heute im Yahoo - Board. Hier wird sich über Kurz oder Lang der Merger auszahlen.
Vielleicht beginnt es ja Heute noch. Die Meldung könnte vielleicht jemand verkürzt übersetzen, Danke?
Schönes Wochenende an alle Vertexianer.
mfg nino

[Kipferl]

hier mal die meldung von yahoo heute

Thursday January 3, 4:00 pm Eastern Time
Press Release
SOURCE: Vertex Pharmaceuticals Incorporated
Aurora Biosciences Signs Assay Development and Screening Collaboration with Allergan
SAN DIEGO and IRVINE, Calif., Jan. 3 /PRNewswire/ -- Aurora Biosciences Corporation today announced a collaboration with Allergan (NYSE: AGN - news) to develop functional cell-based assays for several key G protein-coupled receptor (GPCR) targets, and to screen these targets to identify lead drug candidates. GPCRs are a structurally related target class of cell surface proteins that may play key roles in cellular communication and modulate a variety of biological pathways implicated in the onset and progression of many major human diseases. Allergan and Aurora also recently expanded their existing ion channel collaboration, which was originally signed in January 2001.

Under the agreement, Aurora will develop and screen functional cell-based assays using Aurora`s proprietary Biosensor cell lines and GeneBLAzer(TM) beta-lactamase reporter gene technology to pursue GPCR targets identified and provided by Allergan. Financial terms of the collaboration were not disclosed. This agreement includes an up-front payment to Aurora and payments upon achievement of certain research performance milestones. If lead compounds are identified using screens generated through the collaboration, Aurora will also receive development milestone payments and royalties on the sale of any products that are generated from this collaboration.

``We look forward to working with Aurora Biosciences on this new program,`` stated Lester Kaplan, Ph.D., Allergan`s president of research and development. ``This expanded collaboration will provide us with an enhanced ability to identify novel leads in our GPCR program and bring us closer to identifying potential new therapies addressing unmet medical needs.``

``We are very pleased that Allergan has chosen to expand its partnership with Aurora into an additional area of important drug targets,`` said Harry Stylli, Ph.D., President of Aurora Biosciences. ``Aurora`s world class assay development and screening expertise enables partners to pursue challenging, biologically relevant drug targets and efficiently screen libraries of compounds against them in functional high throughput assays. This collaboration highlights the value of Aurora`s technology and expertise in allowing thorough evaluation and pursuit of key drug targets for pharmaceutical partners.``

Aurora will develop the GPCR screens using proprietary Biosensor cell lines, which may enable the coupling of a wide range of GPCRs to signaling pathways that can be detected optically with great sensitivity. These assays also incorporate other proprietary technologies, including GeneBLAzer(TM) beta-lactamase reporter gene technology, which utilizes a physical property known as fluorescence resonance energy transfer (FRET) to evaluate the possible effects of test compounds on a drug target within a living cell. Allergan`s GPCR targets will be screened against a diverse subset of Aurora`s compound library, which will total more than several hundred thousand small molecules. Following primary screening, Aurora will prioritize hits based on potency, and will then provide the screening data to Allergan for further optimization of lead compounds.

About Aurora

Aurora Biosciences, a wholly-owned subsidiary of Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - news), uses proprietary advances in biology, chemistry and automation to accelerate the discovery of new medicines. Aurora Biosciences` core technologies include a broad portfolio of proprietary fluorescence assay technologies and screening platforms designed to provide an integrated solution for drug discovery. The company also provides target discovery, assay development and screening and other services to its collaborators. Aurora Biosciences` technologies and drug discovery capabilities have been commercially validated by more than 20 major life sciences companies and research organizations, including American Home Products, Becton Dickinson, Bristol-Myers Squibb, Cystic Fibrosis Foundation, Eli Lilly, Families of SMA, Genentech, GlaxoSmithKline, Hereditary Disease Foundation, Johnson & Johnson, Merck, NV Organon Laboratories, Pfizer, Pharmacia and Roche.

This press release contains ``forward-looking`` statements regarding Aurora and Allergan`s ability to discover, develop, and commercialize drug candidates successfully. While Vertex`s management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause actual results to vary materially. These uncertainties include the risk that the agreement between Allergan and Aurora may be terminated by either party, that Aurora may be unable to identify lead compounds, that clinical trials may not result in a marketable product, and that Allergan will be unable to secure regulatory approval of, or successfully market, the drug candidates. Vertex and Allergan disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. For additional information regarding risks and uncertainties, please refer to Allergan`s disclosures in its 2000 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended September 28, 2001.

Agenerase® is a registered trademark of the GlaxoSmithKline group of companies.

SOURCE: Vertex Pharmaceuticals Incorporated


grüsse K.